BioSpace News Archive

Statement of Matthew L. Myers, President, Campaign for Tobacco-Free Kids

EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, announced that it is the winner in this year’s Drug Delivery Technology category given by Fierce Innovation Awards - LifeSciences Edition

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company discovering and developing highly-differentiated therapies, today announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic (PDAC) cancers.

Varian (NYSE: VAR) today announced its first quarter fiscal year 2020 earnings release date.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced that it issued today a conditional notice of redemption for $1.240 billion aggregate principal amount of the Company’s outstanding 5.875% Senior Notes due 2023 (the “2023 Notes”).

NIDA’s annual Monitoring the Future survey shows abuse rates at 2.8%

In this open-label first stage of a 170-patient study, 20 patients with moderate to severe Crohn’s disease will be treated for up to 52 weeks with the novel investigational agent, QBECO SSI, which is designed to restore, rather than suppress, immune function.

The Notes are also convertible into Shares at a conversion price of CAD$2.70, CAD$2.72 and CAD$2.82 per Share, respectively, at any time until the Maturity Date.

First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors

Technavio has announced its latest market research report titled global gene panel market 2020-2024.